Penumbra (PEN) Competitors

Penumbra logo
$319.43 -1.19 (-0.37%)
Closing price 11/17/2026 03:59 PM Eastern
Extended Trading
$320.06 +0.64 (+0.20%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PEN vs. LNTH, ITGR, GEHC, RMD, and DXCM

Should you buy Penumbra stock or one of its competitors? Penumbra's main competitors and comparable companies include Lantheus (LNTH), Integer (ITGR), GE HealthCare Technologies (GEHC), ResMed (RMD), and DexCom (DXCM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Penumbra compare to Lantheus?

Penumbra (NYSE:PEN) and Lantheus (NASDAQ:LNTH) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Penumbra presently has a consensus target price of $367.07, suggesting a potential upside of 14.91%. Lantheus has a consensus target price of $107.44, suggesting a potential upside of 5.54%. Given Penumbra's higher probable upside, equities research analysts plainly believe Penumbra is more favorable than Lantheus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Penumbra
0 Sell rating(s)
14 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.18
Lantheus
0 Sell rating(s)
11 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.21

88.9% of Penumbra shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 2.9% of Penumbra shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Lantheus had 3 more articles in the media than Penumbra. MarketBeat recorded 5 mentions for Lantheus and 2 mentions for Penumbra. Lantheus' average media sentiment score of 0.54 beat Penumbra's score of 0.47 indicating that Lantheus is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Penumbra
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Lantheus
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Penumbra has a beta of 0.71, suggesting that its stock price is 29% less volatile than the broader market. Comparatively, Lantheus has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market.

Lantheus has higher revenue and earnings than Penumbra. Lantheus is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Penumbra$1.40B8.97$177.69M$3.9780.46
Lantheus$1.54B4.32$233.56M$4.0625.07

Lantheus has a net margin of 17.28% compared to Penumbra's net margin of 10.06%. Lantheus' return on equity of 29.26% beat Penumbra's return on equity.

Company Net Margins Return on Equity Return on Assets
Penumbra10.06% 10.39% 8.09%
Lantheus 17.28%29.26%15.40%

Summary

Lantheus beats Penumbra on 10 of the 15 factors compared between the two stocks.

How does Penumbra compare to Integer?

Penumbra (NYSE:PEN) and Integer (NYSE:ITGR) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Penumbra has a beta of 0.71, suggesting that its stock price is 29% less volatile than the broader market. Comparatively, Integer has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

Penumbra presently has a consensus price target of $367.07, suggesting a potential upside of 14.91%. Integer has a consensus price target of $113.67, suggesting a potential downside of 10.49%. Given Penumbra's stronger consensus rating and higher probable upside, research analysts clearly believe Penumbra is more favorable than Integer.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Penumbra
0 Sell rating(s)
14 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.18
Integer
0 Sell rating(s)
11 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.08

Penumbra has higher earnings, but lower revenue than Integer. Integer is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Penumbra$1.40B8.97$177.69M$3.9780.46
Integer$1.85B2.33$102.81M$2.9842.61

In the previous week, Integer had 8 more articles in the media than Penumbra. MarketBeat recorded 10 mentions for Integer and 2 mentions for Penumbra. Integer's average media sentiment score of 1.02 beat Penumbra's score of 0.47 indicating that Integer is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Penumbra
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Integer
6 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Penumbra has a net margin of 10.06% compared to Integer's net margin of 5.68%. Integer's return on equity of 11.84% beat Penumbra's return on equity.

Company Net Margins Return on Equity Return on Assets
Penumbra10.06% 10.39% 8.09%
Integer 5.68%11.84%5.98%

88.9% of Penumbra shares are owned by institutional investors. Comparatively, 99.3% of Integer shares are owned by institutional investors. 2.9% of Penumbra shares are owned by company insiders. Comparatively, 1.1% of Integer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Penumbra beats Integer on 11 of the 16 factors compared between the two stocks.

How does Penumbra compare to GE HealthCare Technologies?

Penumbra (NYSE:PEN) and GE HealthCare Technologies (NASDAQ:GEHC) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

88.9% of Penumbra shares are held by institutional investors. Comparatively, 82.1% of GE HealthCare Technologies shares are held by institutional investors. 2.9% of Penumbra shares are held by insiders. Comparatively, 0.4% of GE HealthCare Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, GE HealthCare Technologies had 9 more articles in the media than Penumbra. MarketBeat recorded 11 mentions for GE HealthCare Technologies and 2 mentions for Penumbra. GE HealthCare Technologies' average media sentiment score of 0.74 beat Penumbra's score of 0.47 indicating that GE HealthCare Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Penumbra
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
GE HealthCare Technologies
2 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Penumbra has a beta of 0.71, meaning that its stock price is 29% less volatile than the broader market. Comparatively, GE HealthCare Technologies has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

Penumbra presently has a consensus price target of $367.07, suggesting a potential upside of 14.91%. GE HealthCare Technologies has a consensus price target of $82.17, suggesting a potential upside of 0.41%. Given Penumbra's higher probable upside, research analysts plainly believe Penumbra is more favorable than GE HealthCare Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Penumbra
0 Sell rating(s)
14 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.18
GE HealthCare Technologies
0 Sell rating(s)
11 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.52

Penumbra has a net margin of 10.06% compared to GE HealthCare Technologies' net margin of 9.96%. GE HealthCare Technologies' return on equity of 20.45% beat Penumbra's return on equity.

Company Net Margins Return on Equity Return on Assets
Penumbra10.06% 10.39% 8.09%
GE HealthCare Technologies 9.96%20.45%5.97%

GE HealthCare Technologies has higher revenue and earnings than Penumbra. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Penumbra$1.40B8.97$177.69M$3.9780.46
GE HealthCare Technologies$20.63B1.79$2.08B$4.7417.27

Summary

Penumbra and GE HealthCare Technologies tied by winning 8 of the 16 factors compared between the two stocks.

How does Penumbra compare to ResMed?

ResMed (NYSE:RMD) and Penumbra (NYSE:PEN) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

In the previous week, ResMed had 7 more articles in the media than Penumbra. MarketBeat recorded 9 mentions for ResMed and 2 mentions for Penumbra. ResMed's average media sentiment score of 0.76 beat Penumbra's score of 0.47 indicating that ResMed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ResMed
7 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Penumbra
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

ResMed has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.71, meaning that its stock price is 29% less volatile than the broader market.

ResMed presently has a consensus target price of $253.69, indicating a potential upside of 6.64%. Penumbra has a consensus target price of $367.07, indicating a potential upside of 14.91%. Given Penumbra's higher possible upside, analysts clearly believe Penumbra is more favorable than ResMed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ResMed
0 Sell rating(s)
11 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.39
Penumbra
0 Sell rating(s)
14 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.18

ResMed has a net margin of 27.79% compared to Penumbra's net margin of 10.06%. ResMed's return on equity of 26.42% beat Penumbra's return on equity.

Company Net Margins Return on Equity Return on Assets
ResMed27.79% 26.42% 19.43%
Penumbra 10.06%10.39%8.09%

ResMed has higher revenue and earnings than Penumbra. ResMed is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResMed$5.65B5.92$1.52B$10.9821.67
Penumbra$1.40B8.97$177.69M$3.9780.46

55.0% of ResMed shares are owned by institutional investors. Comparatively, 88.9% of Penumbra shares are owned by institutional investors. 0.6% of ResMed shares are owned by company insiders. Comparatively, 2.9% of Penumbra shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

ResMed beats Penumbra on 11 of the 16 factors compared between the two stocks.

How does Penumbra compare to DexCom?

Penumbra (NYSE:PEN) and DexCom (NASDAQ:DXCM) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

88.9% of Penumbra shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 2.9% of Penumbra shares are owned by insiders. Comparatively, 0.3% of DexCom shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, DexCom had 8 more articles in the media than Penumbra. MarketBeat recorded 10 mentions for DexCom and 2 mentions for Penumbra. DexCom's average media sentiment score of 0.84 beat Penumbra's score of 0.47 indicating that DexCom is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Penumbra
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
DexCom
3 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Penumbra has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, DexCom has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

DexCom has higher revenue and earnings than Penumbra. DexCom is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Penumbra$1.40B8.97$177.69M$3.9780.46
DexCom$4.66B6.56$836.30M$2.5532.17

DexCom has a net margin of 19.42% compared to Penumbra's net margin of 10.06%. DexCom's return on equity of 37.77% beat Penumbra's return on equity.

Company Net Margins Return on Equity Return on Assets
Penumbra10.06% 10.39% 8.09%
DexCom 19.42%37.77%15.98%

Penumbra presently has a consensus price target of $367.07, suggesting a potential upside of 14.91%. DexCom has a consensus price target of $95.50, suggesting a potential upside of 16.41%. Given DexCom's stronger consensus rating and higher possible upside, analysts clearly believe DexCom is more favorable than Penumbra.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Penumbra
0 Sell rating(s)
14 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.18
DexCom
0 Sell rating(s)
2 Hold rating(s)
24 Buy rating(s)
2 Strong Buy rating(s)
3.00

Summary

DexCom beats Penumbra on 13 of the 17 factors compared between the two stocks.

Get Penumbra News Delivered to You Automatically

Sign up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PEN vs. The Competition

MetricPenumbraHealthcare Equipment & Supplies IndustryHealthcare SectorNYSE Exchange
Market Cap$12.64B$5.99B$7.83B$23.08B
Dividend YieldN/A1.68%2.47%3.82%
P/E Ratio80.4637.4034.0025.99
Price / Sales8.975.398.483.25
Price / Cash74.5823.6221.0115.54
Price / Book7.954.174.463.65
Net Income$177.69M$143.92M$3.52B$1.07B
7 Day Performance-0.73%-5.49%-5.94%-4.19%
1 Month Performance-0.47%-3.68%-4.59%-2.47%
1 Year Performance14.78%-0.11%-1.93%5.85%

Penumbra Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PEN
Penumbra
1.875 of 5 stars
$319.43
-0.4%
$367.07
+14.9%
+14.6%$12.64B$1.40B80.464,700
LNTH
Lantheus
2.412 of 5 stars
$101.01
+0.4%
$107.44
+6.4%
+93.9%$6.60B$1.54B20.311,193
ITGR
Integer
1.5911 of 5 stars
$126.62
+0.0%
$113.67
-10.2%
+89.0%$4.31B$1.85B21.4611,000
GEHC
GE HealthCare Technologies
3.7881 of 5 stars
$84.03
+2.0%
$80.87
-3.8%
+15.9%$38.80B$20.63B17.7354,000
RMD
ResMed
4.3964 of 5 stars
$235.53
+0.1%
$253.69
+7.7%
-2.9%$33.83B$5.65B20.8611,370

Related Companies and Tools


This page (NYSE:PEN) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners